Mercy Gilbert Medical Center

Gilbert, Arizona 85297

3 studies enrolling now · 32 studies all time

What they study most

ASCVD, Acute Coronary Syndrome, Acute Myocardial Infarction (AMI), Angina, Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease (ASCVD), Atrial Fibrillation, Bradycardia, Cardiovascular Disease, Cardiovascular Disease and Lipoprotein(a), Cardiovascular Risk, Congestive Heart Failure

Studies at this site

• Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease — Recruiting now
• An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) — Recruiting now
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Recruiting now
• ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack — Recruiting now
• POLARx Post Approval Study (POLARx PAS) — Completed
• Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS) — Completed
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction — Completed
• Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation — Completed
• EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) — Completed
• Firehawk Rapamycin Target Eluting Coronary Stent North American Trial — Running, not enrolling
• A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation — Stopped early
• Genetic Risk Stratification for Primary Prevention of CAD in Men and Pre & Post-menopausal Women — Status unconfirmed
• Absorb IV Randomized Controlled Trial — Completed
• Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes — Completed
• The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS) — Stopped early
• An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM) — Completed
• A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure — Completed
• Safety and Performance Study of the INGEVITY Lead — Completed
• A Study of VentriGel in Post-MI Patients — Completed
• Quadripolar CRT-D On Currently Approved Lead SystemS — Completed
• Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy — Completed
• To Assess Safety and Efficacy of Myoblast Implantation Into Myocardium Post Myocardial Infarction — Status unconfirmed
• The Dual Antiplatelet Therapy Study (DAPT Study) — Completed
• An Observational Study of Cholesterol in Coronary Arteries — Completed
• ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II — Completed
• Protect II, A Prospective, Multicenter Randomized Controlled Trial — Stopped early
• Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation — Completed